BRISTOL-MYERS SQUIBB COMPANY has filed an Indian patent application IN 9336/DELNP/2008 claiming cyclopropyl fused indolobenzazepine compounds which covers Beclabuvir (BMS-791325) an antiviral drug for the treatment of hepatitis C virus (HCV) infection currently in clinical trials. Beclabuvir acts as a NS5B inhibitor.
IN ‘9336 was entered in India through PCT/US2007/068209 (published as WO 2007/136982), a hearing was offered to applicant on January 22, 2016 regarding the objections raised by the examiner.
Applicant has made his observations / arguments and filed amended set of claims, the examiner was satisfied with respect to all the objections raised previously and allowed the application for grant containing 16 claims, as of now there is no patent number assigned for this application. The decision can be find here.